NITC-6

NITC-6 is a novel naphthalimide-isothiocyanate (ITC) analog designed as a dual inhibitor of DNA topoisomerase II and the PI3K/Akt signaling pathway. Developed by researchers at the Penn State University College of Medicine, NITC-6 was engineered to address the central nervous system (CNS) toxicity associated with the parent compound mitonafide by replacing the N,N-dimethyl group with an isothiocyanate moiety. In preclinical melanoma models, NITC-6 has demonstrated the ability to inhibit cell proliferation, induce apoptosis, and reduce tumor growth by approximately 60% without apparent systemic toxicity. Its mechanism involves the simultaneous inhibition of DNA relaxation by topoisomerase II and the downregulation of pro-survival Akt pathway proteins.